Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: CLDX

Celldex Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for CLDX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (FY2025)$-3.90

Celldex Therapeutics, Inc. (NASDAQ: CLDX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:03 UTC.

What Celldex Therapeutics, Inc. does

Celldex Therapeutics is a biopharmaceutical company focused on developing therapeutic antibodies that target mast cell biology to treat severe inflammatory, allergic, and autoimmune diseases. The company's lead program, barzolvolimab, is a monoclonal antibody being studied across multiple mast cell-driven conditions including Chronic Spontaneous Urticaria, Cold Urticaria, Symptomatic Dermographism, Prurigo Nodularis, and Atopic Dermatitis. The company is also advancing a next-generation bispecific antibody platform, with CDX-622 in early-stage human studies for inflammatory diseases.

Summarized from Celldex Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (FY2025)$-3.90

Revenue, margins & earnings

FY2021: net loss $71M on revenue $5M$5MFY2021FY2022: net loss $112M on revenue $2M$2MFY2022FY2023: net loss $141M on revenue $7M$7MFY2023FY2024: net loss $158M on revenue $7M$7MFY2024FY2025: net loss $259M on revenue $2M$2MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →
Net income for FY2021, FY2022 is the filer’s available-to-common figure (net of preferred dividends) — the filer tags no parent net income for those years.

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-06-29
Most recent filed transactions — June 2026:
  • 2026-06-29SVP & Chief Commercial OfficerIncentive Stock Option (right to buy)Award90,000—
  • 2026-06-29SVP OF REGULATORY AFFAIRSIncentive Stock Option (right to buy)Award95,000—
  • 2026-06-29SVP OF CORP AFFAIRS & ADMIN.Incentive Stock Option (right to buy)Award95,000—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Celldex Therapeutics, Inc. do?

Celldex Therapeutics is a biopharmaceutical company focused on developing therapeutic antibodies that target mast cell biology to treat severe inflammatory, allergic, and autoimmune diseases.

When did CLDX last file with the SEC?

Celldex Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-26. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:03 UTC. This page is also available as JSON at /api/data?ticker=CLDX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for CLDX and 5,000+ tickers.

Create a free account — keep CLDX
For your agent
GET /api/data?ticker=CLDX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt